Antisense and RNAi therapeutics are the new class of drugs used to treat various diseases. They exert their effect by silencing a portion of RNA via short interfering RNAs (siRNAs) or microRNAs (miRNAs) involved in causing the disease or inducing the degradation of targeted mRNA by RNase enzyme and reducing undesirable protein translation. They treat diseases that target nucleic acid and affect the cell growth cycle.
MARKET SCOPE
The "Global Antisense & RNAi Therapeutics Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the antisense & RNAi therapeutics market with detailed market segmentation by type, route of administration, application, and geography. The report provides key statistics on the market status of the leading antisense & RNAi therapeutics market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
- Based on type, the global antisense & RNAi therapeutics market is segmented into RNA interference and antisense RNA.
- On the basis of route of administration, the market is bifurcated into pulmonary delivery, intravenous injections, intra-dermal, intraperitoneal, topical and others.
- Based on application, the market is segmented into infectious diseases, cardiovascular diseases, cancer, neurological disorders and others.
MARKET DYNAMICS
Drivers:
- The increasing prevalence of coronary artery diseases, neurodegenerative disorders, and infectious diseases drive the growth of the antisense & RNAi therapeutics market.
- Growing advancement in the treatment options to target specificity and selectivity fuel market growth.
- The rapid adoption of novel drug delivery and approval and launch of RNA therapeutics boost market growth.
- Growing funding for research and development activities propel market growth.
Restraints:
- High cost of RNA interference-based drugs.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The antisense & RNAi therapeutics market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.
The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the antisense & RNAi therapeutics market in these regions.
IMPACT OF COVID-19 ON ANTISENSE & RNAI THERAPEUTICS MARKET
COVID-19 first began in Wuhan (China) during December 2019, and since then, it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, UK, Turkey, Italy, and Spain are some of the worst affected countries in terms of confirmed cases and reported deaths. During the pandemic outbreak, the market's growth was impacted due to business shutdown, worldwide lockdown, and supply and trade disruptions. There was an increased demand to develop a vaccine for prevention from the Covid-19 virus resulting in R&D activities focus shifting towards the development of the vaccine. This affected the growth of other sectors. However, the market is likely to witness growth due to companies resuming their operations and adapting themselves to the new normal.
MARKET PLAYERS
The report covers key developments in the antisense & RNAi therapeutics market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market players from antisense & RNAi therapeutics market are anticipated to have lucrative growth opportunities in the future with the rising demand for antisense & RNAi therapeutics in the global market.
The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the antisense & RNAi therapeutics market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.
- Alnylam Pharmaceuticals
- Benitec Biopharma Ltd.
- Quark Pharmaceuticals
- Ionis Pharmaceuticals
- Astellas Pharma Inc
- Marina Biosciences
- Sanofi S
- Dicerna Pharmaceuticals
- Tekmira Pharmaceuticals
- Merck